CNS Pharmaceuticals Croissance future

Future contrôle des critères 0/6

CNS Pharmaceuticals devrait augmenter ses bénéfices et ses revenus de 54.7% et de 86.4% par an respectivement, tandis que le BPA devrait croître de croître de 68.5% par an.

Informations clés

54.7%

Taux de croissance des bénéfices

68.5%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	23.7%
Taux de croissance des recettes	86.4%
Rendement futur des capitaux propres	n/a
Couverture par les analystes	Low
Dernière mise à jour	15 Nov 2024

Mises à jour récentes de la croissance future

Recent updates

CNS Pharmaceuticals reports Q2 results

Aug 15

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

Dec 04

CNS Pharmaceuticals sinks after pricing equity offering of $10M

Dec 23

Prévisions de croissance des bénéfices et des revenus

NasdaqCM:CNSP - Estimations futures des analystes et données financières antérieures (USD Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
12/31/2026	N/A	-21	N/A	N/A	1
12/31/2025	N/A	-16	N/A	N/A	1
12/31/2024	N/A	-13	N/A	N/A	1
9/30/2024	N/A	-17	-14	-14	N/A
6/30/2024	N/A	-16	-11	-11	N/A
3/31/2024	N/A	-17	-13	-13	N/A
12/31/2023	N/A	-19	-14	-14	N/A
9/30/2023	N/A	-19	-14	-14	N/A
6/30/2023	N/A	-18	-12	-12	N/A
3/31/2023	N/A	-17	-12	-12	N/A
12/31/2022	N/A	-15	-11	-11	N/A
9/30/2022	N/A	-13	-11	-11	N/A
6/30/2022	N/A	-14	-12	-12	N/A
3/31/2022	N/A	-14	-13	-13	N/A
12/31/2021	N/A	-14	-14	-14	N/A
9/30/2021	N/A	-14	-12	-12	N/A
6/30/2021	N/A	-12	-11	-11	N/A
3/31/2021	N/A	-11	-9	-9	N/A
12/31/2020	N/A	-9	-7	-7	N/A
9/30/2020	N/A	-9	-8	-8	N/A
6/30/2020	N/A	-8	-7	-7	N/A
3/31/2020	N/A	-6	-5	-5	N/A
12/31/2019	N/A	-4	-4	-4	N/A
9/30/2019	N/A	-8	-1	-1	N/A
6/30/2019	N/A	-7	-1	-1	N/A
3/31/2019	N/A	-7	-1	-1	N/A
12/31/2018	N/A	-7	-1	-1	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: CNSP devrait rester non rentable au cours des 3 prochaines années.

Bénéfices vs marché: CNSP devrait rester non rentable au cours des 3 prochaines années.

Croissance élevée des bénéfices: CNSP devrait rester non rentable au cours des 3 prochaines années.

Chiffre d'affaires vs marché: CNSP ne devrait pas générer de revenus l'année prochaine.

Croissance élevée des revenus: CNSP ne devrait pas générer de revenus l'année prochaine.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Données insuffisantes pour déterminer si le retour sur capitaux propres de CNSP devrait être élevé dans 3 ans

CNS Pharmaceuticals Croissance future

Future contrôle des critères 0/6

Informations clés

Mises à jour récentes de la croissance future

Price target increased to US$10.00

Recent updates

CNS Pharmaceuticals Receives Exception by Nasdaq to Regain Compliance with Minimum Bid Price Requirement

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $3 million.

CNS Pharmaceuticals Regains Compliance with Nasdaq Equity Requirement

CNS Pharmaceuticals, Inc. announced that it expects to receive funding from Cortice Biosciences Incorporated

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $5.2 million.

The Nasdaq Hearings Panel Grants the Requested Extension to CNS Pharmaceuticals Until August 12, 2024

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.98075 million.

CNS Pharmaceuticals, Inc. announced a financing transaction

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering in the amount of $1.3725 million.

New major risk - Share price stability

CNS Pharmaceuticals, Inc., Annual General Meeting, Apr 30, 2024

CNS Pharmaceuticals Receives Non-Compliance Letter Form Nasdaq

CNS Pharmaceuticals Provides Non-Compliance Update

CNS Pharmaceuticals, Inc. Appoints Amy Mahery to its Board of Directors

CNS Pharmaceuticals, Inc. has filed a Follow-on Equity Offering.

CNS Pharmaceuticals, Inc. Presents Updated Safety Data from Ongoing Potentially Pivotal Study Evaluating Berubicin in Advance of the Pre-Planned Interim Analysis of Efficacy

New major risk - Negative shareholders equity

CNS Pharmaceuticals, Inc. Opens 46 Clinical Trial Sites Across the U.S., Italy, France, Spain, and Switzerland

Cns Pharmaceuticals, Inc. Announces Enrollment of 200 Patients in Ongoing Potentially Pivotal Study of Berubicin with the Treatment of Glioblastoma Multiforme (Gbm)

CNS Pharmaceuticals Receives Letter from Nasdaq Regarding Non-Compliance with Minimum of $2.5 Million in Stockholders’ Equity Requirement Pursuant to Nasdaq’s Listing Rule 5550(b)(1)

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc., Annual General Meeting, Sep 14, 2023

CNS Pharmaceuticals, Inc. Provides Clinical Trial Update for Ongoing Potentially Pivotal Study with Berubicin for the Treatment of Glioblastoma Multiforme

Bettina M. Cockroft Joins CNS Pharmaceuticals, Inc.'s Board of Directors

CNS Pharmaceuticals Announces First Patient Enrolled in Spain in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Investigator-Initiated Phase 1B/2 Trial to Be Conducted At the Pomeranian Medical University in Poland

Cns Pharmaceuticals, Inc. Appoints Faith Charles as Independent Member and as Chairperson of the Board of Directors

CNS Pharmaceuticals, Inc Announces Preliminary Results from Ongoing Potentially Pivotal Trial Evaluating Berubicin for the Treatment of Recurrent Glioblastoma Multiforme (GBM)

CNS Pharmaceuticals, Inc. has completed a Follow-on Equity Offering.

Insufficient new directors

CNS Pharmaceuticals, Inc. Announces Dosing of First Patient in Europe/France in Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Activation of First Clinical Trial Sites in Europe for Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Provides A Clinical Update of Its Anti-Cancer Drug Candidates Currently in Development for the Treatment of Primary and Metastatic Brain and CNS Cancer

CNS Pharmaceuticals reports Q2 results

CNS Pharmaceuticals, Inc., Annual General Meeting, Jul 27, 2022

CNS Pharmaceuticals Inc. Receives Approval from U.S. FDA for Protocol Amendment to Ongoing Potentially Pivotal Global Trial Evaluating Berubicin for the Treatment of GBM

CNS Pharmaceuticals, Inc. Announces Presentation of Ongoing Potentially Pivotal Berubicin Clinical Trial Design at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting

Price target increased to US$10.00

Insufficient new directors

CNS Pharmaceuticals, Inc. Receives Approval from Competent Authority of Switzerland for Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

CNS Pharmaceuticals, Inc. announced that it expects to receive $11.500001 million in funding

Insufficient new directors

Here's Why We're A Bit Worried About CNS Pharmaceuticals' (NASDAQ:CNSP) Cash Burn Situation

CNS Pharmaceuticals, Inc. Receives Approval from Switzerland Ethics Committee for its Potentially Pivotal Study of Berubicin for the Treatment of Glioblastoma Multiforme

FDA Grants Fast Track Designation to CNS Pharmaceuticals, Inc. for Berubicin for the Treatment of Recurrent Glioblastoma Multiforme

CNS Pharmaceuticals Commences Patient Enrollment in Potentially Pivotal Study of Berubicin

CNS Pharmaceuticals Berubicin Trial is on Schedule to Commence in March 2021

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announces Berubicin Supply Agreement for the Upcoming Clinical Trials

WPD Pharmaceuticals and CNS Pharmaceuticals, Inc. Announce Positive Opinion of the Polish Central Ethics Committee for the WPD-201 Study and Central IRB Study Level Approval for the CNS-201 Study

New 90-day high: US$3.50

CNS Pharmaceuticals Announces It Has Been Featured in Syndicated Broadcast Covering Recent FDA Approval of IND Application

CNS Pharmaceuticals sinks after pricing equity offering of $10M

CNS Pharmaceuticals, Inc. Announces FDA Approval of IND Application for its Brain Cancer Drug Candidate Berubicin

New 90-day high: US$2.89

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance